eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
eXoZymes, Inc.NASDAQ: EXOZ
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $12.74K (cash outflow) fell 70.6% year over year, ahead of the -100.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 20.7% from the prior quarter.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -70.6% holds above the trailing-twelve-month pace of -100.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (27.71K) USD
- Year-over-year change
- -100.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.71K) | -100.1% |
| FY2024 | 2024-12-31 | 18.52M | +1751.8% |
| FY2023 | 2023-12-31 | 1M | -26.2% |
| FY2022 | 2022-12-31 | 1.36M | -41.4% |
| FY2021 | 2021-12-31 | 2.31M | — |
Financing Cash Flow vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.0% is the lowest of 7, against a peer median of +175.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.95M USD | -57.9% | — | 519.7% | |
| LTM Mar 2026 | $35.04M USD | +172.3% | +87.5% | — | |
| LTM Mar 2026 | CA$23.71M CAD | +114.9% | +16.7% | — | |
| LTM Mar 2026 | $20.54M USD | +350.1% | — | — | |
| FY2025 | $10.01M USD | +178.0% | — | — | |
| LTM Mar 2026 | $7.06M USD | +255.3% | -53.4% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $2.81K USD | -100.0% | — | — |
| Peer median (excluding EXOZ) | — | +175.1% | +16.7% | 519.7% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | (52.91K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 198.46K | 216.5K | 281.54K | 1.13M | 1.99M |
| Change in Working Capital | (536.48K) | (190.07K) | 220.31K | (4.02M) | 380.17K |
| Accounts Receivables | (317.07K) | (341.18K) | (72.79K) | 145.04K | 114.72K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (214.43K) | 118.5K | 272.89K | 221.34K | 311.09K |
| Other Working Capital | (4.99K) | 32.61K | 20.21K | (4.38M) | (45.63K) |
| Other Non-Cash Items | (99K) | (35.15K) | 158.73K | (19.4K) | 341.33K |
| Operating Cash Flow | (1.59M) | (1.26M) | (1.18M) | (8.51M) | (6.5M) |
| Capital Expenditures | (422.59K) | (185.98K) | (288.71K) | (396.45K) | (169.92K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 110.33K | 98.77K | (22.46K) | 37.24K | 19.7K |
| Investing Cash Flow | (312.25K) | (87.21K) | (311.17K) | (359.22K) | (150.22K) |
| Debt Repayment | 0 | 0 | 0 | 3.98M | (27.71K) |
| Common Stock Issued | 2.31M | 1.36M | 0 | 14.53M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1M | 11.82K | 0 |
| Financing Cash Flow | 2.31M | 1.36M | 1M | 18.52M | (27.71K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 413.45K | 10.76K | (492.04K) | 9.65M | (6.68M) |
| Free Cash Flow | (2.01M) | (1.44M) | (1.47M) | (8.9M) | (6.67M) |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.